Developmental Cancer Therapeutics Research Program

The scientific goal of the Developmental Cancer Therapeutics Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of-principle, early phase clinical and correlative science studies.

Program Leadership | Kenneth D. Tew, Ph.D., D.Sc.

DCT program leader Ken Tew

Professor and Chair of Cell & Molecular Pharmacology | College of Medicine

Dr. Kenneth D. Tew has served as the Developmental Cancer Therapeutics Program Leader since 2004. He holds the John C. West Endowed Chair in Cancer Research, which is supported by the South Carolina SmartState® Center of Excellence in Translational Cancer Therapeutics. Continuously funded since 1980, his primary scientific contributions focus on the involvement of redox pathways glutathione S-transferases in tumor cell resistance to anticancer drugs.

DCT program themes

Featured Research Project | Elizabeth S. Yeh, Ph.D.

Elizabeth S. Yeh, Ph.D., Assistant Professor of Cell & Molecular Pharmacology, examines how the deregulation of cellular signaling events results in the physiological changes that lead to human cancer, with a specific interest in breast cancer. Working with a team of senior scientists, Dr. Yeh assisted in the identification of a novel AMPK-related protein kinase called Hormonally Up-regulated Neu-associated Kinase (HUNK), whose function has been determined to be critical in the etiology and progression of human breast cancer. Dr. Yeh’s work demonstrated that HUNK promotes the survival of breast cancer cells, further suggesting that this molecule could be a therapeutic target. Dr. Yeh is now working to elucidate the intracellular mechanisms by which HUNK regulates survival signaling through the growth factor receptors, EGFR and HER2, two molecules that are commonly overrepresented in human breast cancer.

Learn more about Dr. Yeh

Shared Resources

To ensure cancer investigators have access to specialized technology and research services, the Hollings Cancer Center supports shared resources that are efficient, cost-effective and provide the latest industry standards for enhanced scientific productivity.

Shared Resources